Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $130,126 | $77,428 | $23,638 | $3,154 |
| % Growth | 68.1% | 227.6% | 649.5% | – |
| Cost of Goods Sold | $13,368 | $9,302 | $2,133 | $599 |
| Gross Profit | $116,758 | $68,126 | $21,505 | $2,555 |
| % Margin | 89.7% | 88% | 91% | 81% |
| R&D Expenses | $237,957 | $134,951 | $108,630 | $104,128 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $144,304 | $117,532 | $92,032 | $68,486 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $382,261 | $252,483 | $200,662 | $172,614 |
| Operating Income | -$265,503 | -$184,357 | -$179,157 | -$170,059 |
| % Margin | -204% | -238.1% | -757.9% | -5,391.9% |
| Other Income/Exp. Net | $5,247 | $243 | -$1,962 | $100,447 |
| Pre-Tax Income | -$260,256 | -$184,114 | -$181,119 | -$69,612 |
| Tax Expense | $346 | $564 | $0 | $0 |
| Net Income | -$260,602 | -$184,678 | -$181,119 | -$69,612 |
| % Margin | -200.3% | -238.5% | -766.2% | -2,207.1% |
| EPS | -4.34 | -3.2 | -3.51 | -1.37 |
| % Growth | -35.6% | 8.8% | -156.2% | – |
| EPS Diluted | -4.34 | -3.2 | -3.51 | -1.37 |
| Weighted Avg Shares Out | 60,995 | 57,673 | 52,121 | 49,600 |
| Weighted Avg Shares Out Dil | 60,995 | 57,673 | 52,121 | 49,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,711 | $13,945 | $4,029 | $447 |
| Interest Expense | $20,603 | $13,892 | $5,201 | $0 |
| Depreciation & Amortization | $1,563 | $1,758 | $1,672 | $1,158 |
| EBITDA | -$238,090 | -$168,464 | -$174,246 | -$68,454 |
| % Margin | -183% | -217.6% | -737.1% | -2,170.4% |